News and Trends 26 Sep 2016 A Colony from a single-cell? All possible with Takara Bio Induced pluripotent stem cells were discovered back in 2006. Since then, they have become a valuable new source of pluripotent cells for research and therapy. And thanks to gene editing technologies, researchers can induce a single mutation in those cells for a broad range of applications. However, the main challenge is the proliferation of a single-cell with […] September 26, 2016 - 3 minutesmins - By Jerome Topsent Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2016 It’s Biotech Week! What’s Up in Europe? The annual celebration of biotech has started! From today through this Sunday, October 2nd, a continent-wide festival, Biotech Week, is happening as part of a larger global affair. Check out the event program and Invest Europe’s infographic on what’s up in Europe! EuropaBio has kicked off the European instalment of global Biotech Week, a week-long series […] September 26, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2016 UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […] September 26, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2016 Terrible Turing hasn’t given up on Toxoplasmosis (or its Karma) The biopharmaceutical company’s Swiss division just published computational studies aiming to improve Daraprim, after its former CEO, Martin Shkreli, attempted to justify the scandalous 5000% price hike as a boost for its R&D. A little over a year ago, Martin Shkreli, founder and then-CEO of Turing Pharmaceuticals, hiked the price of a common medication for toxoplasmosis by […] September 26, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2016 This French Founder is on a mission of Connecting Medical Devices What happens when you mix Internet of Things and Medical Devices? That’s what the French Startup, Instent, and its co-founder, Franz Bozsak, intend to find out. I had a chat with him after he won the EY prize of the Best Parisian Entrepreneur of the Year for his startup. My first question was which language should we speak? Bozsak is […] September 26, 2016 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 24 Sep 2016 The Future of Portugal as explained by Microorganisms Microbiology makes its mark at the first edition of the London Design Biennale taking place in Somerset House. Portugal’s exhibition by Marta de Menezes uses bacteria and viruses to create changing art that represents the future direction of the country. With the common topic “Design by Utopia“, 30 nations have interpreted utopic and dystopic futures using art to […] September 24, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 SELLAS wants to sell us an Immunotherapy for Mesothelioma After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences. City: Zug (Zurich-area), Switzerland Founded: 2012 Employees: 11 – 50 Financial Data: None available…what a secretive cohort. Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on […] September 23, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup A new immuno-oncology startup has taken off with a booming round of VC fundraising. Details on its programs are sparse, but the company’s leadership is a veritable who’s who in German biotech, much like the PayPal Mafia. Immuno-oncology is surely an exciting field, but high-profile leadership is a huge bonus when it comes to attracting […] September 23, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2016 Evotec and Bayer renew their vows and take on Kidney Disease Evotec and Bayer are approaching the 4th anniversary of a successful partnership in endometriosis treatments that made it to clinical trials just last month. To celebrate, they’re starting a new 5-year partnership, this time concerning kidney disease. Evotec has a long list of top-level partners, including Roche, Sanofi, Boehringer Ingelheim and Takeda. After the successful outcome of […] September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2016 After only 6 months, Akarna seals the deal with Allergan for €44.8M upfront Earlier this week, we announced the launch of a new diagnostic tool for NASH by the French company Genfit. Now, Ireland strikes back with the acquisition of Akarna with a €44.8M upfront payment. Akarna focuses on the development of drugs for Non-Alcoholic Steato-Hepatitis (NASH) and boasts to count with a potentially best-in-class therapeutic candidate still in preclinical trials. The […] September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016 A new player has entered the Game: €29M for DDR Cancer Therapy Artios Pharma, launched in May this year, just received €29M (£25M) in Series A to develop cancer treatments. Its technology targets the DNA-Damage Response (DDR) and could overcome one of the main challenges of cancer therapy. Top-notch investors from Europe and the US have eagerly thrown cash at Artios Pharma in their search for new cancer treatments. […] September 21, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016 German Biotech allies with Genentech in battle for Cancer Vaccine BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […] September 21, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email